Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04001595
Other study ID # 23NE0222
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 2013
Est. completion date December 2025

Study information

Verified date January 2024
Source Newcastle University
Contact Patient Registry Manager and Curator
Phone 0191 2418640
Email fkrpregistry@newcastle.ac.uk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Mutations in the Fukutin Related Protein (FKRP) gene cause the condition Limb Girdle Muscular Dystrophy type R9 (LGMDR9) also known as LGMD2I, and the rarer conditions Congenital Muscular Dystrophy (MDC1C), Muscle Eye Brain Disease (MEB) and Walker-Warburg Syndrome (WWS). LGMDR9 is the most common FKRP-related condition, and is especially prevalent in Northern Europe. The aim is to facilitate a questionnaire based research study in order to better characterise and understand the disease globally. By maintaining a global registry this will help identify potential participants eligible for clinical trials in the future.


Description:

The Global FKRP Registry (https://www.fkrp-registry.org/) is an international registry for patients with an FKRP-related condition; no experimental intervention is involved. Patients will receive information on the most up to date standards of care relating to their disease and may be invited to participate in relevant clinical trials. Their data will be updated annually and stored indefinitely, or until they request their data to be removed. The data will be collected via an online form and will be stored on a secure server based in the United Kingdom and looked after by the registry staff at Newcastle University. Data collected from patients will include demographic information, diagnosis, current condition, age of onset, medication, contractures, family history and results of genetic testing, if available. Other optional questionnaires will focus on patients' pain and quality of life. Further information collected from patients' doctors will include, heart and lung function, muscle strength, muscle and brain MRI findings and genetics. The FKRP registry is funded by LGMD2i Research Fund and CureLGMD2i. The primary objectives of the Global FKRP Registry are to: - Accelerate and facilitate clinical trials by locating potential research subjects quickly and efficiently - Facilitate in the planning of clinical trials - Assist the neuromuscular community with the development of recommendations and standards of care - Characterise and describe the FKRP population as a whole, enhancing the understanding of the prevalence throughout the world.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All patients with a confirmed diagnosis of an FKRP-related condition are eligible for inclusion. Diagnosis will be confirmed via genetic testing results. Exclusion Criteria: - There is no exclusion criteria for registration with this patient registry.

Study Design


Intervention

Other:
Patient Registry
Participants who have volunteered to participate will complete various questionnaires relating to their condition.

Locations

Country Name City State
United Kingdom John Walton Muscular Dystrophy Research Centre, Newcastle University Newcastle upon Tyne

Sponsors (4)

Lead Sponsor Collaborator
Newcastle University CureLGMD2i, LGMD2i Research Fund, Ludwig-Maximilians - University of Munich

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

Murphy LB, Schreiber-Katz O, Rafferty K, Robertson A, Topf A, Willis TA, Heidemann M, Thiele S, Bindoff L, Laurent JP, Lochmuller H, Mathews K, Mitchell C, Stevenson JH, Vissing J, Woods L, Walter MC, Straub V. Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9. Ann Clin Transl Neurol. 2020 May;7(5):757-766. doi: 10.1002/acn3.51042. Epub 2020 Apr 28. — View Citation

Richardson M, Mayhew A, Muni-Lofra R, Murphy LB, Straub V. Prevalence of Pain within Limb Girdle Muscular Dystrophy R9 and Implications for Other Degenerative Diseases. J Clin Med. 2021 Nov 25;10(23):5517. doi: 10.3390/jcm10235517. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Patient questionnaire Patient-reported FKRP clinical diagnosis, symptoms relating to muscle weakness, motor function and family history. 12 months
Primary McGill Pain Questionnaire Patient-reported current pain. 12 months
Primary Individualized Neuromuscular Quality of Life questionnaire (INQoL) Patient-reported quality of life. 12 months
Primary Clinician questionnaire Doctor-reported clinical data, including respiratory and cardiac test results and genetic confirmation of FKRP mutation. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05409079 - Schulze Muscular Dystrophy Ability Clinical Study N/A
Active, not recruiting NCT05906251 - A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) Phase 1
Recruiting NCT05230459 - A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) Phase 1/Phase 2
Recruiting NCT03981289 - Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)
Completed NCT02836418 - Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 1/Phase 2
Active, not recruiting NCT03930628 - Limb-Girdle Muscular Dystrophy Type 2I in Norway
Recruiting NCT05618080 - Trial Readiness and Endpoint Assessment in LGMD R1
Completed NCT01066455 - Cardiac Outcome Measures in Children With Muscular Dystrophy N/A
Active, not recruiting NCT05206617 - 3 Year Follow up on ANO5 Patients
Completed NCT01126697 - Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies Phase 2/Phase 3
Withdrawn NCT02245711 - Cell Therapy in Limb Girdle Muscular Dystrophy Phase 1
Withdrawn NCT02050776 - Stem Cell Therapy in Limb Girdle Muscular Dystrophy Phase 1
Active, not recruiting NCT05876780 - A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) Phase 1
Recruiting NCT06378203 - Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] N/A
Completed NCT04202627 - Biomarker Development in LGMD2i
Not yet recruiting NCT06390566 - Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts
Completed NCT01081080 - Cardiac Magnetic Resonance in Children With Muscular Dystrophy N/A
Recruiting NCT05102799 - MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants

External Links